Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels.
Aylwin
Simon
S
D000172:Acromegaly / Q000097:blood / Q000175:diagnosis*; D017024:Chemotherapy, Adjuvant; D003692:Delayed-Action Preparations; D013006:Growth Hormone / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D015282:Octreotide; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D013004:Somatostatin; D013006:Growth Hormone; D015282:Octreotide